ESR2 and prostate cancer: In addition, overexpression of ERβ also reduced cell viability, migration, and inflammation and enhanced apoptosis in PC-3 and DU145 cells by suppressing lipopolysaccharide (LPS)-induced activation of NFkB that represents another driver of prostate cancer progression and mediator of inflammation [49].